HUMAN PAPILLOMAVIRUS (HPV) AND CYTOMEGALOVIRUS (CMV) THERAPEUTICS MARKET ANALYSIS

Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published In : Jun 2019
Code : CMI2707
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics MarketSize and Trends

The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market was valued at US$ 3,006.4 million in 2018, and is expected to witness a CAGR of 6.0% during the forecast period (2018– 2026).

Figure 1. Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)

Source: Coherent Market Insights Analysis (2019)

Increasing number of sexually transmitted infections is expected to drive growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market

Increasing number of sexually transmitted infections is one of major drivers for the market growth. For instance, according to World Health Organization’s (WHO) report in 2019, over 290 million women suffer from HPV infection worldwide, annually and over 1 million people suffer from sexually transmitted infections (STIs) every day, worldwide.

Moreover, increasing approvals for vaccines is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in October 2018, the U.S Food and Drug Administration (FDA) approved Gardasil 9 ( HPV 9-valent vaccine), developed by Merck & Co., Inc. Gardasil 9 is used for cervical, vulvar, vaginal, and anal cancers caused by HPV types.

Figure 2: Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value (US$ Mn), By Region, 2018